Advisers could pocket up to $100 million in fees from Johnson & Johnson’s $30 billion acquisition of Swiss biotech firm Actelion , the largest takeover of a European healthcare business in more than a decade. Four investment banks will share the advisory pot; J&J could cough up $30-$40 million in fees to its advisers, Lazard and Citi, while Actelion is expected to pay $45-$60 million to Bank of America and Credit Suisse, according to estimates from Thomson Reuters/Freeman Consulting.
Category: J and J Snack Foods
Despite Soft Guidance, J&J Remains a Good Long-Term Buy
The blue-chip multinational has a good mix of prescription and over-the-counter products, which makes it well-suited to weather volatility. Shares of Johnson & Johnson sank 1.72% on Tuesday following softer-than-expected guidance for 2017.
2 Healthcare Stocks With Better Dividends Than HCP, Inc.
The healthcare-focused real estate investment trust still offers a juicy yield, but the shares of certain companies poised to generate increasing profits could generate far more income over the long run. Here’s why Amgen At recent prices, HCP, Inc.’s $0.37 quarterly payment offers a 5% forward yield, which is higher than J&J and Amgen offer right now.
J&J’s Decision to Walk Away Set Stage for Renewed Actelion Talks
Johnson & Johnson’s willingness to walk away from talks to acquire Swiss biotechnology company Actelion Ltd. for about $28 billion is the very thing that got the two sides back to the negotiating table. This week, amid rising pressure from shareholders, Actelion surprised investors and re-entered negotiations with J&J, which signaled a willingness to raise its offer if granted exclusivity, said people familiar with the matter.
Actelion Enters Exclusive Takeover Discussions with J&J
Actelion said on Wednesday it has entered exclusive negotiations with U.S. healthcare company Johnson & Johnson regarding what the Swiss biotech company called a “possible strategic transaction”.